Results 1 to 10 of about 261,930 (145)

Neutrophil gelatinase-associated lipocalin (NGAL) predicts response to neoadjuvant chemotherapy and clinical outcome in primary human breast cancer [PDF]

, 2012
In our previous work we showed that NGAL, a protein involved in the regulation of proliferation and differentiation, is overexpressed in human breast cancer (BC) and predicts poor prognosis.
Arnold, Norbert, Ataseven, Beyhan, Bauer, Maret, Darb-Esfahani, Silvia, Denkert, Carsten Michael, Hamann, Sigrid, Holzhausen, Hans-Jürgen, Jonat, Walter, Khandan, Fariba, Loibl, Sibylle, Mehta, Keyur, Minckwitz, Gunther von, Mundhenke, Christoph, Müller, Berit, Park, Hyerim, Schem, Christian, Thomssen, Christoph, Weimer, Joerg, Wenners, Antonia Sophie   +18 more
core   +19 more sources

The Relationship between Pathological Features and 18F-FDG PET/CT that Changed the Surgeon's Decision as Neoadjuvant Therapy in Breast Cancer

World Journal of Nuclear Medicine, 2022
Objective Patients diagnosed with breast cancer and decided to undergo surgical treatment can undergo neoadjuvant therapy following their 2-deoxy-2-[fluorine-18]fluoro-D-glucose positron emission tomography/computed tomography (18F-FDG PET/CT) findings ...
Akay Edizsoy, Ahmet Dağ, Pınar Pelin Özcan, Zehra Pınar Koç   +3 more
doaj   +1 more source

Relationship of dose to vascular target volumes and local failure in pancreatic cancer patients undergoing neoadjuvant chemoradiation

Frontiers in Oncology, 2022
ObjectiveThe objectives of this study were to evaluate whether dose to the vasculature is associated with local control after surgery in patients with borderline resectable (BLR) and resectable pancreatic cancer (PCA) receiving neoadjuvant radiation ...
Bailey Nelson, Michelle Barrord, Kyle Wang, Nolan A. Wages, Nolan A. Wages, Mickaela Sudhoff, Jordan Kharofa   +6 more
doaj   +1 more source

Efficacy and safety of neoadjuvant immunotherapy combined with chemoradiotherapy or chemotherapy in esophageal cancer: A systematic review and meta-analysis

Frontiers in Immunology, 2023
BackgroundSignificant progress has been made in the investigation of neoadjuvant immune-chemoradiotherapy (NICRT) and neoadjuvant immune-chemotherapy (NICT) on the outcomes of esophageal cancer patients.
Yunsong Liu, Yongxing Bao, Xu Yang, Shuang Sun, Meng Yuan, Zeliang Ma, Wanting Zhang, Yirui Zhai, Yang Wang, Yu Men, Jianjun Qin, Liyan Xue, Jun Wang, Zhouguang Hui   +13 more
doaj   +1 more source

Neoadjuvant Nivolumab and Ipilimumab for Nonmetastatic Renal Cell Carcinoma with Tumor Thrombus [PDF]

Journal of Immunotherapy and Precision Oncology, 2023
Renal cell carcinoma with level IV tumor thrombus is a condition necessitating aggressive surgical management. Many solid organ malignancies often benefit from neoadjuvant treatments for tumor debulking and improvement of surgical outcomes.
Viraj A. Master, Benjamin N. Schmeusser, Adeboye O. Osunkoya, Arnold R. Palacios, Eric Midenberg, Lauren Yantorni, Kenneth Ogan, Mehmet A. Bilen   +7 more
doaj   +1 more source

Merkel Cell Carcinoma: An Immunotherapy Fairy-Tale?

Frontiers in Oncology, 2021
Merkel cell carcinoma (MCC) is a rare, highly aggressive, neuroendocrine cutaneous tumor. The incidence of MCC is growing worldwide, and the disease-related mortality is about three-fold higher than melanoma.
Enrica Teresa Tanda, Enrica Teresa Tanda, Agostina Lagodin d’Amato, Agostina Lagodin d’Amato, Giovanni Rossi, Giovanni Rossi, Elena Croce, Elena Croce, Andrea Boutros, Andrea Boutros, Federica Cecchi, Francesco Spagnolo, Paola Queirolo   +12 more
doaj   +1 more source

Neoadjuvant tislelizumab combined with chemotherapy in locally advanced oral or oropharyngeal squamous cell carcinoma: a real−world retrospective study

Frontiers in Immunology, 2023
ObjectivesThe treatment of locally advanced oral or oropharyngeal squamous cell carcinoma (LAOOPSCC) is surgery and radiotherapy or chemoradiotherapy but with unsatisfactory survival rate.
Wen-Jie Wu, Wen-Jie Wu, Wen-Jie Wu, Qian Liu, Qian Liu, Qian Liu, Pu-Gen An, Pu-Gen An, Pu-Gen An, Lin Wang, Lin Wang, Lin Wang, Jian-Yun Zhang, Jian-Yun Zhang, Jian-Yun Zhang, Yan Chen, Yan Chen, Yan Chen, Tong Zhang, Jie Zhang, Jie Zhang, Jie Zhang   +21 more
doaj   +1 more source

Breast cancer: Monitoring response to neoadjuvant chemotherapy using Tc-99m sestamibi scintimammography [PDF]

, 2003
Background: Aim of the study was to assess the value of scintimammography using Tc-99m sestamibi in the evaluation of tumor response to neoadjuvant chemotherapy.
Brinkbäumer, K., Hahn, K., Keßler, M., Linke, R., Sommer, H., Tiling, R., Untch, M.   +6 more
core   +1 more source

Neoadjuvant chemotherapy and trastuzumab versus neoadjuvant chemotherapy followed by post-operative trastuzumab for patients with HER2-positive breast cancer [PDF]

, 2015
Neoadjuvant chemotherapy plus trastuzumab (NCT) increases the rate of pathological complete response (pCR) and event-free survival (EFS) compared to neoadjuvant chemotherapy (NC) alone in women with HER2 positive breast cancer (BC).
Ades, F, Ahmed, R, Asher, R, Beresford, M, De Azambuja, E, Gojis, O, Howell, SJ, Januszewski, A, Lewanski, C, Lythgoe, D, Macpherson, IRJ, Owadally, W, Palmieri, C, Riddle, P, Shah, D, Stanley, B, Yan, K   +16 more
core   +2 more sources

Neoadjuvant endocrine therapy for luminal breast cancer treatment: a first-choice alternative in times of crisis such as the COVID-19 pandemic [PDF]

, 2020
The epidemiological emergency caused by CoV-2 (COVID-19) has changed priorities in breast cancer management. In those places where the pandemic has had the greatest effect, it is of paramount importance for most patients to be at home, reducing or ...
Martí, Covadonga, Sánchez-Méndez, José I.   +1 more
core   +1 more source